Description A look 12 years into the future at how the risks of AL and ATTR will be managed and the diseases treated. Contributors Raymond Comenzo, MD Dr. Raymond Comenzo received his medical degree from Boston University School of Medicine. He completed his internship and residency in medicine at Boston City Hospital, followed by his fellowship in hematology/oncology at New England Medical Center. Dr. Comenzo is Professor of Medicine and Pathology at Tufts University School of Medicine and Director of the Blood Bank and Stem Cell Processing Laboratory. Dr. Comenzo is board certified in internal medicine, medical oncology, and hematology. He is a member of the International Myeloma Working Group; the Scientific Advisory Board, International Myeloma Foundation, the Eastern Clinical Oncology Group (ECOG), Myeloma Committee and a board member of the Amyloidosis Research Consortium (ARC). In addition he holds memberships in the Massachusetts Medical Society, American Society of Hematology (ASH), and the American Association of Blood Banks. Dr. Comenzo is also a reviewer for Transfusion, Journal of Clinical Apheresis, Blood, Journal of Clinical Oncology, New England Journal of Medicine, Leukemia, Cancer Research, and Haematologica. His major research interests include autologous stem cell transplantation and novel therapies for systemic amyloidosis, gene silencing therapy for light-chain diseases, and the role of proteasome inhibitors in plasma cell diseases. Dr. Comenzo was a member of the AF Board of Directors for many years. He is currently a member of the Scientific Advisory Board of the Amyloidosis Foundation and has been since 2006.